ࡱ> HI l \pThe Free Software Foundation B=PF0*8X@"1 Helvetica1Courier1 Courier New1 Courier New1 Helvetica$#,##0_);($#,##0)$#,##0_);[Red]($#,##0)$#,##0.00_);($#,##0.00)$#,##0.00_);[Red]($#,##0.00)-**_($* #,##0_);_($* (#,##0);_($* "-"_);_(@_)*)'_(* #,##0_);_(* (#,##0);_(* "-"_);_(@_)5,2_($* #,##0.00_);_($* (#,##0.00);_($* "-"??_);_(@_)2+/_(* #,##0.00_);_(* (#,##0.00);_(* "-"??_);_(@_)2$#,##0.00;[Red]$#,##0.003$#,##0.00;[Red]($#,##0.00)4$#,##0;[Red]($#,##00)50.00%;[Red](0.00%)6 0%;[Red](0%)7#,##0.00;[Red](#,##0.00)8#,##0;[Red](#,##0)                + ) , *   Ј ~~ ؈ ~~#؈ ~~"؈ ~~7#܈ ~~ ؈ ~~8#܈ ~~83ffff̙̙3f3fff3f3f33333f33&Item 901 Financial Statements aTABLE OF CONTENTS.TABLE OF CONTENTS (1)LTABLE OF CONTENTS (2)bTABLE OF CONTENTS (3)&IN WITNESS WHEREOF each of the %NOTICE OF BENEFICIAL OWNERSHIP l     dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??TABLE OF CONTENTSTABLE OF CONTENTS (1)TABLE OF CONTENTS (2)TABLE OF CONTENTS (3)!IN WITNESS WHEREOF each of the  NOTICE OF BENEFICIAL OWNERSHIPU } I } $ } :      !Akebia Therapeutics, Inc. 8-K 06/28/20183+Item 9.01 Financial Statements and Exhibits Exhibit  Description of Exhibit Number   @ 1 )Agreement and Plan of Merger, dated as of  8 0June 28, 2018, by and among Akebia Therapeutics,2*Inc., Alpha Therapeutics Merger Sub, Inc.,+#and Keryx Biopharmaceuticals, Inc.*333333$@/'Notes Conversion Agreement, dated as of80June 28, 2018, by and among Akebia Therapeutics,,$Inc., Keryx Biopharmaceuticals, Inc.,$and Baupost Group Securities, L.L.C.fffffX@4,Voting Agreement, dated as of June 28, 2018,0(by and between Akebia Therapeutics, Inc.,$and Baupost Group Securities, L.L.C.X@Joint Press Release$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/DIlsg[O+ml7}5=PF0*8X> @ l  < -  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??!Item 901 Financial Statements aTABLE OF CONTENTS (1)TABLE OF CONTENTS (2)TABLE OF CONTENTS (3)!IN WITNESS WHEREOF each of the  NOTICE OF BENEFICIAL OWNERSHIPU } } $ } 8} $ } } $ <     !Akebia Therapeutics, Inc. 8-K 06/28/2018TABLE OF CONTENTS ARTICLE 1 THE MERGER  ~       )\(?   The Merger  ~    RQ?  Closing  ~    {Gz?  Effective Time  ~   p= ף?Effects of the Merger~  ?/'Certificate of Incorporation and Bylaws~  $of the Surviving Corporation(\?7/Directors and Officers of Surviving Corporation~ Q?2*Treatment of Keryx Shares and Keryx Equity~ AwardsHzG?+#Closing of the Keryx Transfer Books~ q= ףp?/'Exchange Fund; Exchange of Certificates~ ? Withholding~ "(\?'Adjustments to Prevent Dilution~ "Q?Further Action~ "Gz?Post-Merger Operations~ &0(ARTICLE 2 REPRESENTATIONS AND WARRANTIES~ &OF KERYXGz@( Organization and Corporate Power~ *)\(@2*Authorization; Valid and Binding Agreement~ *D lui9lx8'~=% !"#$%&'()*+,-./0123456789:; = ףp=@   Capital Stock  ~ * !RQ@!! Subsidiaries!!~ !2!"ffffff@"" No Breach""~ "2"#{Gz@## Consents, etc##~ #2#$(\@$7$/SEC Reports; Disclosure Controls and Procedures$$~ $6$%p= ף@%"%No Undisclosed Liabilities%%~ %>%&Q@&'&Absence of Certain Developments&&~ &>&'@''Compliance with Laws''~ '>'(zG@((Title to Properties((~ (B()(\@)) Tax Matters))~ )B)* ףp= @*!*Contracts and Commitments**~ *J*+Q@++Intellectual Property++~ +V+,333333@,, Litigation,,~ ,^,-HzG@-- Insurance--~ -b-.\(\@..Employee Benefit Plans..~ .b./q= ףp@///'Environmental Compliance and Conditions//~ /j/0Q@0$0Employment and Labor Matters00~ 0j01@1"1FDA and Regulatory Matters11~ 1n12Gz@22 Brokerage22~ 2~23(\@33 Disclosure33~ 3~34ףp= @4"4Ownership of Akebia Shares44~ 4~45@55Opinion55~ 5~56Gz@6/6'No Other Representations and Warranties66~ 6678$9____________________________1:)Created by Morningstar Document Research.0;(http://documentresearch.morningstar.com/< /a`u*S| @g=PF0*8X> @2;;::99  l  @=OK  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??!Item 901 Financial Statements aTABLE OF CONTENTSTABLE OF CONTENTS (2)TABLE OF CONTENTS (3)!IN WITNESS WHEREOF each of the  NOTICE OF BENEFICIAL OWNERSHIPU } } $ } 8} $ } $} $ @     !Akebia Therapeutics, Inc. 8-K 06/28/2018TABLE OF CONTENTSE =ARTICLE 3 REPRESENTATIONS AND WARRANTIES OF AKEBIA AND MERGER  ~   SUB    Gz@ (  Organization and Corporate Power  ~   )\(@ 2 *Authorization; Valid and Binding Agreement  ~  = ףp=@ Capital Stock~ RQ@ Subsidiaries~ ffffff@ No Breach~ {Gz@ Consents, etc~ (\@7/SEC Reports; Disclosure Controls and Procedures~ p= ף@"No Undisclosed Liabilities~ Q@'Absence of Certain Developments~ @Compliance with Laws~ zG@Title to Properties~ (\@ Tax Matters~  ףp= @!Contracts and Commitments~ Q @Intellectual Property~ 333333 @ Litigation~ HzG @ Insurance~ \(\ @Employee Benefit Plans~ q= ףp @/'Environmental Compliance and Conditions~ Q @$Employment and Labor Matters~  @"FDA and Regulatory Matters~ D luige/;JkS^ !"#$%&'()*+,-./0123456789:;<=>? Gz @   Brokerage  ~  !(\ @!! Disclosure!!~ !!"ףp= @"!"Ownership of Keryx Shares""~ ""# @##Opinion##~ ##$Gz @$$ Merger Sub$$~ $$%)\( @%/%'No Other Representations and Warranties%%~ %%&&/''ARTICLE 4 COVENANTS RELATING TO CONDUCT''~ ''( OF BUSINESS)))* ףp= @**Covenants of Keryx**~ **+Gz@++Covenants of Akebia++~ ++,Q@,,,$No Control of Other Party?s Business,,~ ,,--5.-ARTICLE 5 ADDITIONAL COVENANTS OF THE PARTIES..~ ..///0 ףp= @00 Investigation00~ 001Gz@121*Registration Statement and Proxy Statement11~ 1122 2for Shareholder Approval3Q@33Shareholders? Meetings33~ 334)\(@44Non-Solicitation44~ 445333333@545,Regulatory Approvals; Additional Agreements;55~ 5566!6Performance of Merger Sub7= ףp=@7"7Employee and Labor Matters77~ 778HzG@818)Indemnification of Officers and Directors88~ 8"89RQ@99Public Disclosure99~ 9&9:\(\@:+:#NASDAQ Listing of Additional Shares::~ :*:;<$=____________________________1>)Created by Morningstar Document Research.0?(http://documentresearch.morningstar.com/D& l5]t\N_GO't=PF0*8X> @B??>>==..((''   l  4YSb  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??!Item 901 Financial Statements aTABLE OF CONTENTSTABLE OF CONTENTS (1)TABLE OF CONTENTS (3)!IN WITNESS WHEREOF each of the  NOTICE OF BENEFICIAL OWNERSHIPU } } $ } 6} $ } $} $ 4     !Akebia Therapeutics, Inc. 8-K 06/28/2018TABLE OF CONTENTS ffffff@   Takeover Laws  ~ *  q= ףp@   Section 16  ~ *  {Gz@  Convertible Notes  ~ *  Q@  Stockholder Litigation  ~ *  (\@   Cooperation  ~ . @ Tax Matters~ .p= ף@ Resignation of Directors~ .'ARTICLE 6 CONDITIONS TO CLOSING~ . ףp= @.&Conditions to All Parties? Obligations~ .Gz@/'Conditions to Akebia?s and Merger Sub?s~ 2 ObligationsQ@)!Conditions to Keryx?s Obligations~ 6)\(@Waiver of Conditions~ :ARTICLE 7 TERMINATION~ : ףp= @ Termination~ :Gz@Effect of Termination~ >Q@Termination Fees~ BARTICLE 8 MISCELLANEOUS~ JDU luiFg% XkSu !"#$%&'()*+,-./0123   !Q @!!Expenses!!~ !J!" ףp= @"" Amendment""~ "J"#(\ @##Waiver##~ #N#$Gz @$5$-No Survival of Representations and Warranties$$~ $N$% @%&%Entire Agreement; Counterparts%%~ %N%&Q @&$&Applicable Law; Jurisdiction&&~ &R&'p= # @''Waiver of Jury Trial''~ 'R'()\( @(( Assignability((~ (R()Gz. @)$)No Third Party Beneficiaries))~ )V)*333333 @**Notices**~ *V*+Q8 @++Certain Definitions++~ +Z+,= ףp= @,%,Other Definitional Provisions,,~ ,,-(\B @-- Severability--~ --.HzG @..Specific Performance..~ ../0$1____________________________12)Created by Morningstar Document Research.03(http://documentresearch.morningstar.com/,w|x(6]2=PF0*8X> @2332211 l  L%o({?  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??!Item 901 Financial Statements aTABLE OF CONTENTSTABLE OF CONTENTS (1)TABLE OF CONTENTS (2)!IN WITNESS WHEREOF each of the  NOTICE OF BENEFICIAL OWNERSHIPU } m} $ } 0.} $ } } $ L     !Akebia Therapeutics, Inc. 8-K 06/28/2018TABLE OF CONTENTS ARTICLE I EFFECTIVENESS  ~       Section 1.1.   Effectiveness  ~     ARTICLE II DEFINITIONS  ~    Section 2.1. Definitions~   Section 2.2.%Other Interpretive Provisions~ 'ARTICLE III REGISTRATION RIGHTS~  Section 3.1.Demand Registration~  Section 3.2.Shelf Registration~  Section 3.3.Piggyback Registration~ & Section 3.4.Lock-Up Agreements~ . Section 3.5.Registration Procedures~ . Section 3.6.Underwritten Offerings~ FD lui-0 u[K' !"#$%&'()*+,-./0123456789:;<=>?   ! Section 3.7.!.!&No Inconsistent Agreements; Additional!!~ !J!"""Rights###$ Section 3.8.$$Registration Expenses$$~ $J$%%%& Section 3.9.&&Indemnification&&~ &N&'''( Section 3.10.(+(#Rules 144 and 144A and Regulation S((~ (Z()))* Section 3.11.*(* Existing Registration Statements**~ *Z*++ ,ARTICLE IV MISCELLANEOUS,,~ ,^,---. Section 4.1...Authority; Effect..~ .^.///0 Section 4.2.00Notices00~ 0^01112 Section 4.3.2-2%Termination and Effect of Termination22~ 2b23334 Section 4.4.44Permitted Transferees44~ 4b45556 Section 4.5.66Remedies66~ 6b67778 Section 4.6.88 Amendments88~ 8f8999: Section 4.7.:: Governing Law::~ :f:;;;< Section 4.8.<<Consent to Jurisdiction<<~ <f<===> Section 4.9.>>WAIVER OF JURY TRIAL>>~ >j>???D lT*kP,;lHC _@ABCDEFGHIJK@ Section 4.10.@#@Merger; Binding Effect, Etc@@~ @j@AAAB Section 4.11.BB CounterpartsBB~ BjBCCCD Section 4.12.DD SeverabilityDD~ DjDEEEF Section 4.13.FF No RecourseFF~ FjFGH$I____________________________1J)Created by Morningstar Document Research.0K(http://documentresearch.morningstar.com/^\8=PF0*8X> @:KKJJII,,   l    dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??!Item 901 Financial Statements aTABLE OF CONTENTSTABLE OF CONTENTS (1)TABLE OF CONTENTS (2)TABLE OF CONTENTS (3) NOTICE OF BENEFICIAL OWNERSHIPU } } $ } } $      !Akebia Therapeutics, Inc. 8-K 06/28/2018kcIN WITNESS WHEREOF, each of the undersigned has duly executed this Agreement as of the date first a Company:   ! AKEBIA THERAPEUTICS, INC.         By:       Name:       Title:   Investor:( BAUPOST GROUP SECURITIES, L.L.C. By: Name:Title:$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/64;/#f6,si]Q)=PF0*8X> @*  l    dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??!Item 901 Financial Statements aTABLE OF CONTENTSTABLE OF CONTENTS (1)TABLE OF CONTENTS (2)TABLE OF CONTENTS (3)!IN WITNESS WHEREOF each of the U } } $      !Akebia Therapeutics, Inc. 8-K 06/28/2018&NOTICE OF BENEFICIAL OWNERSHIP By:   Name:   Title:    $____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/&?@th\8~=PF0*8X> @ Root Entry FBook  D  !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFG